Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2004 Jun 1;380(Pt 2):353–360. doi: 10.1042/BJ20040062

Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Jack U Flanagan 1, Jean-Didier Maréchal 1, Richard Ward 1, Carol A Kemp 1, Lesley A McLaughlin 1, Michael J Sutcliffe 1, Gordon C K Roberts 1, Mark J I Paine 1, C Roland Wolf 1
PMCID: PMC1224184  PMID: 14992686

Abstract

Although the residues that determine the preference of CYP2D6 (cytochrome P450 2D6) for compounds containing a basic nitrogen are well characterized, the contribution of other active site residues to substrate binding and orientation is less well understood. Our structural model of CYP2D6 identifies the aromatic residue Phe120 as a likely major feature of the active site. To examine the role of Phe120, mutants of CYP2D6 in which this residue has been substituted by alanine, leucine, tyrosine, serine, histidine, tryptophan or methionine residues have been prepared in bacterial membranes co-expressing human cytochrome NADPH cytochrome P450 oxidoreductase. The mutants have been characterized using the prototypical bufuralol 1' hydroxylase and dextromethorphan O- and N-demethylase activities of CYP2D6. Larger effects on K(m) values are observed for dextromethorphan O-demethylation than for bufuralol 1' hydroxylation, indicating that the Phe120 side chain is more important in dextromethorphan than in bufuralol binding. A role for this side chain in determining the regiospecificity of substrate oxidation was indicated by changes in the relative rates of O- and N-demethylation of dextromethorphan and, notably, by the formation of 7-hydroxy dextromethrophan, a novel dextromethorphan metabolite, in mutants in which it had been substituted. Computational studies of dextromethorphan binding to the active site of the Phe120-->Ala mutant were carried out to throw light on the way in which the removal of this side chain leads to different modes of ligand binding.

Full Text

The Full Text of this article is available as a PDF (444.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  2. Ekins S., de Groot M. J., Jones J. P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab Dispos. 2001 Jul;29(7):936–944. [PubMed] [Google Scholar]
  3. Ellis S. W., Hayhurst G. P., Smith G., Lightfoot T., Wong M. M., Simula A. P., Ackland M. J., Sternberg M. J., Lennard M. S., Tucker G. T. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem. 1995 Dec 8;270(49):29055–29058. doi: 10.1074/jbc.270.49.29055. [DOI] [PubMed] [Google Scholar]
  4. Ghahramani P., Ellis S. W., Lennard M. S., Ramsay L. E., Tucker G. T. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137–144. doi: 10.1046/j.1365-2125.1997.05382.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Grace J. M., Kinter M. T., Macdonald T. L. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem Res Toxicol. 1994 May-Jun;7(3):286–290. doi: 10.1021/tx00039a003. [DOI] [PubMed] [Google Scholar]
  6. Guengerich F. Peter, Hanna Imad H., Martin Martha V., Gillam Elizabeth M. J. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry. 2003 Feb 11;42(5):1245–1253. doi: 10.1021/bi027085w. [DOI] [PubMed] [Google Scholar]
  7. Guengerich F. Peter, Miller Grover P., Hanna Imad H., Martin Martha V., Léger Serge, Black Cameron, Chauret Nathalie, Silva José M., Trimble Laird A., Yergey James A. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry. 2002 Sep 10;41(36):11025–11034. doi: 10.1021/bi020341k. [DOI] [PubMed] [Google Scholar]
  8. Haining R. L., Jones J. P., Henne K. R., Fisher M. B., Koop D. R., Trager W. F., Rettie A. E. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry. 1999 Mar 16;38(11):3285–3292. doi: 10.1021/bi982161+. [DOI] [PubMed] [Google Scholar]
  9. Hanna I. H., Kim M. S., Guengerich F. P. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch Biochem Biophys. 2001 Sep 15;393(2):255–261. doi: 10.1006/abbi.2001.2510. [DOI] [PubMed] [Google Scholar]
  10. Hayhurst G. P., Harlow J., Chowdry J., Gross E., Hilton E., Lennard M. S., Tucker G. T., Ellis S. W. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochem J. 2001 Apr 15;355(Pt 2):373–379. doi: 10.1042/0264-6021:3550373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hiroi T., Kishimoto W., Chow T., Imaoka S., Igarashi T., Funae Y. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology. 2001 Sep;142(9):3901–3908. doi: 10.1210/endo.142.9.8363. [DOI] [PubMed] [Google Scholar]
  12. Islam S. A., Wolf C. R., Lennard M. S., Sternberg M. J. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis. 1991 Dec;12(12):2211–2219. doi: 10.1093/carcin/12.12.2211. [DOI] [PubMed] [Google Scholar]
  13. Jones G., Willett P., Glen R. C., Leach A. R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997 Apr 4;267(3):727–748. doi: 10.1006/jmbi.1996.0897. [DOI] [PubMed] [Google Scholar]
  14. Jones G., Willett P., Glen R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol. 1995 Jan 6;245(1):43–53. doi: 10.1016/s0022-2836(95)80037-9. [DOI] [PubMed] [Google Scholar]
  15. Kirton Stewart B., Kemp Carol A., Tomkinson Nicholas P., St-Gallay Steven, Sutcliffe Michael J. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins. 2002 Nov 1;49(2):216–231. doi: 10.1002/prot.10192. [DOI] [PubMed] [Google Scholar]
  16. Koymans L., Vermeulen N. P., van Acker S. A., te Koppele J. M., Heykants J. J., Lavrijsen K., Meuldermans W., Donné-Op den Kelder G. M. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol. 1992 Mar-Apr;5(2):211–219. doi: 10.1021/tx00026a010. [DOI] [PubMed] [Google Scholar]
  17. Kunkel T. A., Roberts J. D., Zakour R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
  18. Lin L. Y., Di Stefano E. W., Schmitz D. A., Hsu L., Ellis S. W., Lennard M. S., Tucker G. T., Cho A. K. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos. 1997 Sep;25(9):1059–1064. [PubMed] [Google Scholar]
  19. Macdonald T. L., Gutheim W. G., Martin R. B., Guengerich F. P. Oxidation of substituted N,N-dimethylanilines by cytochrome P-450: estimation of the effective oxidation-reduction potential of cytochrome P-450. Biochemistry. 1989 Mar 7;28(5):2071–2077. doi: 10.1021/bi00431a016. [DOI] [PubMed] [Google Scholar]
  20. Mackman R., Tschirret-Guth R. A., Smith G., Hayhurst G. P., Ellis S. W., Lennard M. S., Tucker G. T., Wolf C. R., Ortiz de Montellano P. R. Active-site topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants. Arch Biochem Biophys. 1996 Jul 1;331(1):134–140. doi: 10.1006/abbi.1996.0291. [DOI] [PubMed] [Google Scholar]
  21. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  22. Mancy A., Broto P., Dijols S., Dansette P. M., Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry. 1995 Aug 22;34(33):10365–10375. doi: 10.1021/bi00033a007. [DOI] [PubMed] [Google Scholar]
  23. McCann S. J., Pond S. M., James K. M., Le Couteur D. G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci. 1997 Dec 9;153(1):50–53. doi: 10.1016/s0022-510x(97)00179-2. [DOI] [PubMed] [Google Scholar]
  24. Modi S., Gilham D. E., Sutcliffe M. J., Lian L. Y., Primrose W. U., Wolf C. R., Roberts G. C. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry. 1997 Apr 15;36(15):4461–4470. doi: 10.1021/bi962633p. [DOI] [PubMed] [Google Scholar]
  25. Niwa T., Yabusaki Y., Honma K., Matsuo N., Tatsuta K., Ishibashi F., Katagiri M. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539–547. doi: 10.1080/004982598239290. [DOI] [PubMed] [Google Scholar]
  26. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964 Jul;239:2370–2378. [PubMed] [Google Scholar]
  27. Paine Mark J. I., McLaughlin Lesley A., Flanagan Jack U., Kemp Carol A., Sutcliffe Michael J., Roberts Gordon C. K., Wolf C. Roland. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem. 2002 Nov 22;278(6):4021–4027. doi: 10.1074/jbc.M209519200. [DOI] [PubMed] [Google Scholar]
  28. Pritchard M. P., Glancey M. J., Blake J. A., Gilham D. E., Burchell B., Wolf C. R., Friedberg T. Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics. 1998 Feb;8(1):33–42. doi: 10.1097/00008571-199802000-00005. [DOI] [PubMed] [Google Scholar]
  29. Pritchard M. P., Ossetian R., Li D. N., Henderson C. J., Burchell B., Wolf C. R., Friedberg T. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch Biochem Biophys. 1997 Sep 15;345(2):342–354. doi: 10.1006/abbi.1997.0265. [DOI] [PubMed] [Google Scholar]
  30. Renaud J. P., Peyronneau M. A., Urban P., Truan G., Cullin C., Pompon D., Beaune P., Mansuy D. Recombinant yeast in drug metabolism. Toxicology. 1993 Oct 5;82(1-3):39–52. doi: 10.1016/0300-483x(93)90058-z. [DOI] [PubMed] [Google Scholar]
  31. Sali A., Blundell T. L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993 Dec 5;234(3):779–815. doi: 10.1006/jmbi.1993.1626. [DOI] [PubMed] [Google Scholar]
  32. Smith D. A. Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica. 1997 May;27(5):513–525. doi: 10.1080/004982597240479. [DOI] [PubMed] [Google Scholar]
  33. Smith G., Modi S., Pillai I., Lian L. Y., Sutcliffe M. J., Pritchard M. P., Friedberg T., Roberts G. C., Wolf C. R. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity. Biochem J. 1998 May 1;331(Pt 3):783–792. doi: 10.1042/bj3310783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Smith G., Stanley L. A., Sim E., Strange R. C., Wolf C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 1995;25:27–65. [PubMed] [Google Scholar]
  35. Smith G., Stubbins M. J., Harries L. W., Wolf C. R. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998 Dec;28(12):1129–1165. doi: 10.1080/004982598238868. [DOI] [PubMed] [Google Scholar]
  36. Verdonk Marcel L., Cole Jason C., Hartshorn Michael J., Murray Christopher W., Taylor Richard D. Improved protein-ligand docking using GOLD. Proteins. 2003 Sep 1;52(4):609–623. doi: 10.1002/prot.10465. [DOI] [PubMed] [Google Scholar]
  37. Williams Pamela A., Cosme Jose, Ward Alison, Angove Hayley C., Matak Vinković Dijana, Jhoti Harren. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003 Jul 13;424(6947):464–468. doi: 10.1038/nature01862. [DOI] [PubMed] [Google Scholar]
  38. Yu A., Dong H., Lang D., Haining R. L. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos. 2001 Nov;29(11):1362–1365. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES